Remove Books Remove FDA Remove Labelling
article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As folks steeped in the world of generic drugs And Hatch-Waxman know, theres a lot that happens before FDA can take action on an ANDA.

FDA 96
article thumbnail

Q&A: How gluten-free processed foods put people with celiac disease at risk

STAT

The story of how the food industry went gaga for gluten-free products, putting the health of people with celiac at risk in the process, takes center stage in Emily Abel’s new book, “Gluten Free for Life: Celiac Disease, Medical Recognition, and the Food Industry.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

pharmaphorum

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. billion in sales for AZ last year, a rise of around 25%, while Merck booked just under $1 billion from the drug.

FDA 140
article thumbnail

Skinny Label and Induced Infringement: The Saga Continues

The FDA Law Blog

government in the now-infamous (at least in FDA circles) Teva v. GSK skinny label case , the U.S. The Government’s concern goes far beyond this case: Like many generic drug sponsors, the Government raises concerns of the implications of the outcome of this case on the skinny label pathway itself.

article thumbnail

AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

pharmaphorum

The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priority review. billion in sales for AZ last year, while Merck booked $725 million from the drug. million new cases per year.

FDA 111
article thumbnail

ViiV, J&J get FDA nod for simpler HIV injectable dosing

pharmaphorum

The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away with the need for an oral lead-in period. The post ViiV, J&J get FDA nod for simpler HIV injectable dosing appeared first on.

FDA 98
article thumbnail

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

pharmaphorum

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Lucentis (ranibizumab) for leading causes of blindness, raising the prospect of a cheaper treatment option for US patients. Sales reached a peak in 2019, when Roche booked $1.8 billion, but fell back to $1.4

FDA 72